VEGFA and glioblastoma: These findings suggest that, while anti-VEGF therapies did not historically show an OS benefit in phase III trials, a specific subset of patients with recurrent glioblastoma exhibiting this peculiar diffusion MRI phenotype may actually have a survival benefit with anti-VEGF agents.